#pharma
Indian firms commit $20.5 billion investment in US; Pharma dominates with $19.1 billion
The pharmaceutical sector accounted for the vast majority of the financial commitment, with planned investments exceeding $19.1 billion, led by Sun Pharmaceutical Industries Ltd
Emcure hits the “sweet spot” on weightloss brand Poviztra, says executive
Emcure's Poviztra weight loss brand thrives post-price cut, contributing to $1 billion revenue milestone for FY26.
Emcure doubling down on biosimilars pipeline: MD Satish Mehta
Emcure currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. While it has developed these in-house so far, the drugmaker will also scout for partners with products not in their pipeline, for commercialisation…
clinicaltrials-mcp added to PyPI
Conversational access to ClinicalTrials.gov — an MCP server for pharma analysts, CRO teams, and health-tech builders
Ahead of Market: 10 things that will decide stock market action on Tuesday
Indian markets ended higher driven by positive election trends, with gains in financials, pharma, and metals. Nifty held above key support levels despite range-bound movement. Analysts see bullish momentum intact, though global cues remain weak and near-term …
Rituximab Biosimilars Market Trastuzumab Biosimilars Market Research Analysis Report 2026: $6.2 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key opportunities in the rituximab biosimilars market include the launch of new biosimilar formulations, expansion of subcutaneous delivery options, and increasing adoption in emerging markets. Rising prevalence of non-Hodgkin's lymphoma and autoimmune diseas…
Trastuzumab Biosimilars Market Analysis Report 2026: $24.48 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
The trastuzumab biosimilars market is expanding due to increasing cancer prevalence, loss of patent exclusivity, and cost-effective therapies. Opportunities abound in biosimilar expansions, physician confidence, untapped regional markets, and favorable reimbu…
Ahead of Market: 10 things that will decide stock market action on Tuesday
The Nifty 50 and BSE Sensex rebounded on broad-based buying led by pharma, IT, auto and metals. Volatility eased, while analysts signalled resistance ahead, suggesting a range-bound trend with stock-specific opportunities amid global uncertainty.